Fierce Pharma
SEPTEMBER 9, 2024
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing facility in its home country. The U.K. | With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing facility in its home country.
MedCity News
SEPTEMBER 9, 2024
In an age where consumers have more options than ever about where to receive their care, improving the financial experience through embedded finance can give providers an advantage in an increasingly competitive marketplace. The post How Embedded Finance Creates a Better Patient Experience appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 9, 2024
Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO, Anat Ashkenazi, the company didn’t have to look far. | Lilly on Monday revealed that it’s slotting 23-year company veteran Lucas Montarce into the finance chief role after the pharma’s previous CFO, Anat Ashkenazi, announced her departure in early June.
MedCity News
SEPTEMBER 9, 2024
Losing these retail medication outlets creates more than just pharmacy deserts. In many low-income and underserved areas, drugstores also serve as grocery stores and hubs for essential services, and hence their closures mean communities lose crucial access points for a variety of goods and services. The post There is Still a Significant Need for Community Pharmacies appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 9, 2024
After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own deal after opting not to join in on Teva's $4.25 billion national opioid settlement.
MedCity News
SEPTEMBER 9, 2024
The American Medical Association released a new report on Monday on pharmacy benefit managers. It explained that there is low competition among PBMs and high vertical integration with payers. The post AMA Report Details Low Competition in PBM Market appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
SEPTEMBER 9, 2024
In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Meghan Mullooly, Archbow Consulting’s Vice President, offers advice to pharma manufacturers for successfully applying digital solutions to their patient support programs.
MedCity News
SEPTEMBER 9, 2024
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class. The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News.
European Pharmaceutical Review
SEPTEMBER 9, 2024
A report from Frontier Economics has highlighted the major benefit industry clinical trials have had on UK’s economy. For instance, it has supported its growth and the job market, the research showed. Of the 65,000 jobs generated, 21,000 individuals were employed directly by the pharmaceutical industry to deliver trials, according to the data. While industry clinical trials in the UK have reduced , the Association of the British Pharmaceutical Industry (ABPI) stated that if the activity assumes
MedCity News
SEPTEMBER 9, 2024
At a recent conference, Maria Berkman — who serves as head of medtech at Broadview Ventures and managing director at Longview Ventures — shared insights into the somewhat niche ecosystem of medtech investment. The post 3 Things to Know About Medtech Investment, From a VC appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
SEPTEMBER 9, 2024
Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC.
PharmaVoice
SEPTEMBER 9, 2024
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
pharmaphorum
SEPTEMBER 9, 2024
AI biomarker could help identify lung cancer patients most likely to benefit from AstraZeneca and Daiichi Sankyo's TROP2 drug Dato-DXd.
Pharmaceutical Technology
SEPTEMBER 9, 2024
PRV-3279 is under clinical development by Sanofi and currently in Phase II for Systemic Lupus Erythematosus.
PharmaTech
SEPTEMBER 9, 2024
CDER’s Jonathan Chapman, senior policy advisor, and Takeda’s Paulien Groll, head of Compliance Excellence, discussed how companies can be proactive with their CAPA strategies instead of reactive, at the 2024 PDA/FDA Joint Regulatory Conference.
Pharmaceutical Technology
SEPTEMBER 9, 2024
KOS-1803 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
pharmaphorum
SEPTEMBER 9, 2024
House of Representatives votes in favour of BIOSECURE Act, which will stop businesses in the US from contracting with Chinese firms on national security grounds
PharmaTimes
SEPTEMBER 9, 2024
Research suggests that LLMs could be used to support trainee doctors, nurses and GPs
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
SEPTEMBER 9, 2024
NICE backs NHS of MSD's Welireg for cancers associated with von Hippel-Lindau (VHL) disease after earlier rejection
MedCity News
SEPTEMBER 9, 2024
Any successful response to skyrocketing drug costs has to also actively manage medications at the individual level — just because someone can be on a medication doesn’t mean they should be. The post It’s Time to Actively Manage Medications at the Individual Level appeared first on MedCity News.
Clarivate
SEPTEMBER 9, 2024
Did you know that over 80% of executives rank innovation among their top three priorities, yet only 10% are satisfied with their organization’s innovation performance [1] ? This striking gap underscores the critical need for robust patent benchmarking data to inform better decision-making and drive innovation success. Our latest report, “Innovators to Watch 2024,” shines a spotlight on the organizations on the cusp of breaking into the Clarivate Top 100 Global Innovators rankings.
Pharmaceutical Commerce
SEPTEMBER 9, 2024
The latest news for pharma industry insiders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
SEPTEMBER 9, 2024
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Papillary Thyroid Cancer.
PharmExec
SEPTEMBER 9, 2024
Results of the FENopta study found that after one year of treatment, 96% of patients experienced no relapses of multiple sclerosis, with an annualized relapse rate of just 0.04.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Merkel Cell Carcinoma.
Impetus Digital
SEPTEMBER 9, 2024
Our client, a leader in the endocrinology sector, faced the challenge of launching a product in new indications without established treatment guidelines. To navigate this complex scenario, they turned to Impetus Digital’s innovative virtual platform and strategic experts. Through a combination of asynchronous data reviews, insight-gathering, patient journey mapping, and treatment pathway profiling plus real-time virtual Scientific Workshops , the endocrinology KOLs were able to reach a consensus
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Spotio
SEPTEMBER 9, 2024
Short for revenue operations, RevOps is the alignment of Marketing, Sales, and Support functions to improve the customer experience and increase revenue growth. RevOps is important because it helps connect internal teams, drive consistent revenue growth, increase customer happiness and retention, and boost company-wide efficiency metrics. In other words, RevOps will help your organization do what it does more effectively.
PharmaTech
SEPTEMBER 9, 2024
In this paper, the authors introduce a method that combines ion exchange chromatography with an easier-to-perform, simpler one-step post-column derivatization that is selective to nitrite and visible spectrophotometric detection to allow high sample loading volumes without affecting resolution.
Infuse Medical
SEPTEMBER 9, 2024
With uses going beyond entertainment and into vital sectors like surgery, augmented reality (AR) is transforming the healthcare sector. AR gives surgeons better vision by overlaying digital data onto the physical world, therefore enabling them to execute difficult treatments with more confidence and accuracy. By 2024 there will be an estimated 1.7 billion mobile augmented reality (AR) users worldwide, a rise of 1.5 billion from the 200 million seen in 2015.
PharmExec
SEPTEMBER 9, 2024
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
217 
Let's personalize your content